Unlock instant, AI-driven research and patent intelligence for your innovation.

Antisense oligonucleotides targeting alpha-synuclein and uses thereof

A technology of antisense oligonucleotide and synuclein, which is used in medical preparations containing active ingredients, anti-animal/human immunoglobulins, peptide sources, etc.

Pending Publication Date: 2020-10-23
BRISTOL MYERS SQUIBB CO +1
View PDF70 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Medication costs can easily exceed $2,500 per year for a single person, and therapeutic procedures can cost as much as $100,000 per patient

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antisense oligonucleotides targeting alpha-synuclein and uses thereof
  • Antisense oligonucleotides targeting alpha-synuclein and uses thereof
  • Antisense oligonucleotides targeting alpha-synuclein and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0319] Example 1: Construction of ASO

[0320] The antisense oligonucleotides described herein are designed to target multiple regions in the SNCA pre-mRNA. see Figure 1A is the genome SNCA sequence, Figure 1B is the SNCA cDNA. For example, constructing an ASO to target using such as figure 2 Regions indicated by the pre-mRNA start and pre-mRNA stop sites of NG_011851.1 and / or the mRNA start and stop sites of its mRNA are indicated. exist figure 2 and image 3Exemplary sequences (eg, SEQ ID numbers) for ASOs are described in . In some embodiments, ASOs are designed as gapmers (eg, alternating gapmers). See DES number.

[0321] figure 2 and image 3 Non-limiting examples of ASO designs for selected sequences are shown. The same method can be applied to any other sequence disclosed herein. The gapmers were constructed to contain locked nucleic acid - LNA (capital letters). For example, gapmers can have β-deoxy LNAs at the 5' and 3' ends with a phosphorothioate bac...

Embodiment 2A

[0323] Example 2A: High Assay to Measure SNCA Protein Reduction in Primary Neurons

[0324] The ability of SNCA-targeted ASOs to reduce SNCA protein expression was tested in primary mouse neurons. From PAC-Tg (SNCA A53T ) + / + ;SNCA - / - Primary neuronal cultures were established from the forebrain of ("PAC-A53T") mice carrying the complete human SNCA gene with the A53T mutation in a mouse SNCA knockout background. See Kuo Y et al., Hum Mol Genet., 19:1633-50 (2010). All procedures involving mice were performed according to animal testing methods (ATM) approved by the Bristol-Myers Squibb Animal Care and Use Committee (ACUC). Primary neurons were generated by papain digestion according to the manufacturer's protocol (Worthington Biochemical Corporation, LK0031050). Isolated neurons were washed and resuspended in Neurobasal medium supplemented with B27 (Gibco), 1.25 μM Glutamax (Gibco), 100 units / ml penicillin, 100 μg / ml streptomycin, and 25 μg / ml amphotericin B ( NBM, Invi...

Embodiment 2B

[0328] Example 2B: Spontaneous Calcium Oscillation Measurements

[0329] Reduced oscillations in intracellular free calcium concentrations (calcium oscillations) correspond to increased neurotoxicity and, therefore, may indicate reduced in vivo tolerance. To measure spontaneous calcium oscillations in primary cortical neurons, rat primary cortical neurons were prepared from Sprague-Dawley rat embryos (E19). Briefly, cerebral cortex was dissected and incubated in papain / DNase / Earle's Balanced Salt Solution (EBSS) solution at 37°C for 30-45 minutes. After triturating and centrifuging the cell pellet, the reaction was stopped by incubation with EBSS containing protease inhibitors, bovine serum albumin (BSA) and DNase. Cells were then triturated and washed with Neurobasal (NB, Invitrogen) supplemented with 2% B-27, 100 μg / ml penicillin, 85 μg / ml streptomycin and 0.5 mM glutamine.

[0330] Cells were plated at a concentration of 25,000 cells / well in 384-well poly-D-lysine-coated ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.

Description

[0001] References to Sequence Listings Submitted Electronically [0002] The contents of the electronically filed Sequence Listing (name: 3338.109PC01_SequenceListing_ST25.txt, size: 13,817 bytes; creation date: January 10, 2019) filed in this application are incorporated herein by reference in their entirety. technical field [0003] The present disclosure relates to antisense oligomeric compounds (ASOs) that target the intron-exon junction of alpha-synuclein (SNCA) transcripts in cells, resulting in decreased expression of alpha-synuclein (SNCA) protein . Reduction of SNCA protein expression can be beneficial in a number of medical diseases such as multiple system atrophy, Parkinson's disease, Parkinson's disease dementia (PDD) and dementia with Lewy bodies. Background technique [0004] Alpha-synuclein (SNCA), a member of the synuclein family, is a small, soluble protein expressed primarily in nerve tissue. See Marques O et al., Cell Death Dis. 19:e350 (2012). It is ex...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/113C07K14/47
CPCC07K14/4711C12N15/113C12N2310/11C12N2310/315C12N2310/3231C12N2310/341C12N2310/346C07K14/47C12N2310/321C12N2310/3521C07K16/18A61K31/7088A61P25/16A61P25/28A61K2039/505A61K9/0085A61K39/3955C12N2310/31C12N2310/3341C12N2310/351C12N2320/31C12N2320/32
Inventor R·E·奥尔森A·M·卡拉斯小杰雷·E·梅雷迪思N·迪韦齐斯J·K·洛伊C·J·巴尔迪克A·潘德里I·M·麦克唐纳P·哈格多恩M·L·詹森
Owner BRISTOL MYERS SQUIBB CO